Study: Selenium may cut men’s risk of diabetes
NEW YORK A recent study published in BioMed Central’s open access journal, Nutrition and Metabolism, has shown that men with a higher concentration of selenium in their bodies are less likely to develop diabetes.
Tasnime Akbaraly, from the University of Montpellier, worked with a team of researchers to follow 1,162 healthy French men and women for nine years, monitoring plasma selenium concentrations and incidence of dysglycemia. Akbaraly said during the study period, 127 new cases of dysglycemia occurred, of which 70 were in men and 57 in women. She pointed out, however, that elderly men with high plasma selenium concentrations were “significantly associated with a lower risk of developing dysglycemia over the following nine years.”
“The reason we observed a protective effect of selenium in men but not in women is not completely clear, but might be attributed to women being healthier at baseline, having better antioxidant status in general and possible differences in how men and women process selenium,” Akbaraly said.
Selenium, a trace mineral that is an essential element in several metabolic pathways and is found in such foods as walnuts and various types of fish.
Bausch & Lomb makes Renu Fresh packaging user-friendly
ROCHESTER, N.Y. Bausch & Lomb on Friday announced the relaunch of Renu Fresh multi-purpose contact lens solution in a clear bottle in order for contact lens wearers to see exactly how much solution is remaining.
The new packaging is also easier to recycle, making it more environmentally friendly, B&L stated.
Valeant buys OTC, generic drug maker
ALISO VIEJO, Calif. A U.S. drug maker has bought a manufacturer of branded generics and OTC products in Brazil.
Valeant Pharmaceuticals International announced Friday that it had bought the company for $28 million. The company, which was not named in Valeant’s statement on the matter, mostly makes dermatology drugs and had annual sales of around $19 million in 2009.
“We are excited to advance our dermatology presence in the Brazilian market, which is one of the leading dermatology markets worldwide,” Valeant chairman and CEO J. Michael Pearson said. “This acquisition gets us closer to building the critical mass we need in the Brazilian pharmaceutical market.”